{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:57:32Z","timestamp":1791107852452,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2013,12,8]],"date-time":"2013-12-08T00:00:00Z","timestamp":1386460800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2014,11]]},"DOI":"10.1007\/s00535-013-0921-z","type":"journal-article","created":{"date-parts":[[2013,12,7]],"date-time":"2013-12-07T10:19:14Z","timestamp":1386411554000},"page":"1504-1513","source":"Crossref","is-referenced-by-count":64,"title":["Hepatocarcinogenesis in chronic hepatitis C patients achieving a sustained virological response to interferon: significance of lifelong periodic cancer screening for improving outcomes"],"prefix":"10.1007","volume":"49","author":[{"given":"Naoki","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aritsune","family":"Ohho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miho","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiro","family":"Kotoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Kajiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,12,8]]},"reference":[{"issue":"suppl 19","key":"921_CR1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00535-008-2251-0","volume":"44","author":"T Uemura","year":"2009","unstructured":"Uemura T, Ichijo T, Yoshizawa K, et al. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44(suppl 19):102\u20137.","journal-title":"J Gastroenterol"},{"key":"921_CR2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0140-6736(95)91739-X","volume":"346","author":"S Nishiguchi","year":"1995","unstructured":"Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051\u20135.","journal-title":"Lancet"},{"key":"921_CR3","doi-asserted-by":"crossref","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT study group. Inhibition of hepatocarcinogenesis by interferon therapy. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"921_CR4","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124\u201330.","journal-title":"Hepatology"},{"key":"921_CR5","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875\u201381.","journal-title":"Ann Intern Med"},{"key":"921_CR6","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S0168-8278(99)80196-2","volume":"30","author":"T Okanoue","year":"1999","unstructured":"Okanoue T, Itoh Y, Minami M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999;30:653\u20139.","journal-title":"J Hepatol"},{"key":"921_CR7","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(00)03595-9","volume":"357","author":"S Nishiguchi","year":"2001","unstructured":"Nishiguchi S, Shiomi S, Nakatani S, et al. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis. Lancet. 2001;357:196\u20137.","journal-title":"Lancet"},{"key":"921_CR8","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2009.12.028","volume":"52","author":"AC Cardoso","year":"2010","unstructured":"Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C with advanced fibrosis. J Hepatol. 2010;52:652\u20137.","journal-title":"J Hepatol"},{"key":"921_CR9","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1046\/j.1365-2893.2000.00241.x","volume":"7","author":"H Toyoda","year":"2000","unstructured":"Toyoda H, Kumada T, Tokuda A, et al. Long-term follow-up of sustained responders to interferon therapy in patients with chronic hepatitis C. J Viral Hepat. 2000;7:414\u20139.","journal-title":"J Viral Hepat"},{"key":"921_CR10","first-page":"593","volume":"23","author":"N Enokimura","year":"2003","unstructured":"Enokimura N, Shiraki K, Kawakita T, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 2003;23:593\u20136.","journal-title":"Anticancer Res"},{"key":"921_CR11","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s00535-004-1519-2","volume":"40","author":"M Ikeda","year":"2005","unstructured":"Ikeda M, Fujiyama S, Tanaka M, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148\u201356.","journal-title":"J Gastroenterol"},{"key":"921_CR12","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1440-1746.2005.03800.x","volume":"20","author":"H Tokita","year":"2005","unstructured":"Tokita H, Fukui H, Tanaka A, et al. Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy. J Gastroenterol Hepatol. 2005;20:752\u20138.","journal-title":"J Gastroenterol Hepatol"},{"key":"921_CR13","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1478-3231.2006.01406.x","volume":"27","author":"S Kobayashi","year":"2007","unstructured":"Kobayashi S, Takeda T, Enomoto M, et al. Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients. Liver Int. 2007;27:186\u201391.","journal-title":"Liver Int"},{"key":"921_CR14","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.2169\/internalmedicine.47.1087","volume":"47","author":"M Hirakawa","year":"2008","unstructured":"Hirakawa M, Ikeda K, Arase Y, et al. Hepatocarcinogenesis following HCV RNA eradication by interferon in chronic hepatitis patients. Intern Med. 2008;47:1637\u201343.","journal-title":"Intern Med"},{"key":"921_CR15","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1093\/jac\/dks269","volume":"67","author":"KC Chang","year":"2012","unstructured":"Chang KC, Hung CH, Lu SN, et al. A novel predictive score for hepatocellular carcinoma development in patients with chronic hepatitis C after sustained response to pegylated interferon and ribavirin combination therapy. J Antimicrob Chemother. 2012;67:2766\u201372.","journal-title":"J Antimicrob Chemother"},{"key":"921_CR16","doi-asserted-by":"crossref","first-page":"7218","DOI":"10.3748\/wjg.v11.i45.7218","volume":"11","author":"Y Ito","year":"2005","unstructured":"Ito Y, Yamamoto N, Nakata R, et al. Delayed development of hepatocellular carcinoma during long-term follow-up after eradication of hepatitis C virus by interferon therapy. World J Gastroenterol. 2005;11:7218\u201321.","journal-title":"World J Gastroenterol"},{"key":"921_CR17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1757-1626-2-18","volume":"2","author":"T Mashitani","year":"2009","unstructured":"Mashitani T, Yoshiji H, Yamazaki M, et al. Development of hepatocellular carcinoma in a patient 13\u00a0years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009;2:18.","journal-title":"Cases J"},{"key":"921_CR18","author":"V Conteduca","year":"2013","unstructured":"Conteduca V, Sansonno D, Russi S, et al. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J Infect. 2013. doi: 10.1016\/j.jinf.2013.08.019 .","journal-title":"J Infect"},{"key":"921_CR19","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"IM Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405\u201316.","journal-title":"N Engl J Med"},{"key":"921_CR20","doi-asserted-by":"crossref","unstructured":"Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-na\u00efve genotype 1 hepatitis C: The randomized PILLAR study. Hepatology. 2013;58:1918\u201329.","DOI":"10.1002\/hep.26641"},{"key":"921_CR21","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.jhep.2004.02.007","volume":"40","author":"S Zeuzem","year":"2004","unstructured":"Zeuzem S, Hultcrantz R, Bourliere M, et al. Peginterferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotype 2 or 3. J Hepatol. 2004;40:993\u20139.","journal-title":"J Hepatol"},{"issue":"1","key":"921_CR22","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/S1665-2681(19)31382-1","volume":"12","author":"JJ Urquijo","year":"2013","unstructured":"Urquijo JJ, Diago M, Boadas J, et al. Safety and efficacy of treatment with pegylated interferon alpha-2a with ribavirin in chronic hepatitis C genotype 4. Ann Hepatol. 2013;12(1):30\u20135.","journal-title":"Ann Hepatol"},{"key":"921_CR23","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/hep.1840190629","volume":"19","author":"VJ Desmet","year":"1994","unstructured":"Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology. 1994;19:1513\u201320.","journal-title":"Hepatology"},{"issue":"2 suppl 1","key":"921_CR24","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1002\/lt.20034","volume":"10","author":"JM Llovet","year":"2004","unstructured":"Llovet JM, Fuster J, Bruix J, Barcelona-Clinic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10(2 suppl 1):S115\u201320.","journal-title":"Liver Transpl"},{"key":"921_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","volume":"158","author":"RL Morgan","year":"2013","unstructured":"Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329\u201337.","journal-title":"Ann Intern Med"},{"key":"921_CR26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0168-8278(99)80370-5","volume":"31","author":"M Colombo","year":"1999","unstructured":"Colombo M. Natural history and pathogenesis of hepatitis C virus-related hepatocellular carcinoma. J Hepatol. 1999;31:25\u201330.","journal-title":"J Hepatol"},{"key":"921_CR27","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/S0168-8278(98)80339-5","volume":"28","author":"K Ikeda","year":"1998","unstructured":"Ikeda K, Saitoh S, Suzuki Y, et al. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation of 2215 patients. J Hepatol. 1998;28:930\u20138.","journal-title":"J Hepatol"},{"key":"921_CR28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/alcalc\/35.3.286","volume":"35","author":"KN Khan","year":"2000","unstructured":"Khan KN, Yatsuhashi H. Effect of alcohol consumption on the progression of hepatitis C virus infection and risk of hepatocellular carcinoma in Japanese patients. Alcohol. 2000;35:286\u201395.","journal-title":"Alcohol"},{"key":"921_CR29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00535-010-0293-6","volume":"46","author":"M Tateyama","year":"2011","unstructured":"Tateyama M, Yatsuhashi H, Taura N, et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. J Gastroenterol. 2011;46:92\u2013100.","journal-title":"J Gastroenterol"},{"key":"921_CR30","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1111\/j.1572-0241.2001.03780.x","volume":"96","author":"A Sangiovanni","year":"2001","unstructured":"Sangiovanni A, Colombo E, Radaelli F, et al. Hepatocyte proliferation and risk of hepatocellular carcinoma in cirrhotic patients. Am J Gastroenterol. 2001;96:1575\u201380.","journal-title":"Am J Gastroenterol"},{"key":"921_CR31","doi-asserted-by":"crossref","first-page":"972","DOI":"10.3892\/etm.2012.709","volume":"4","author":"N Taura","year":"2012","unstructured":"Taura N, Fukuda S, Ichikawa T, et al. Relationship of \u03b1-fetoprotein levels and development of hepatocellular carcinoma in hepatitis C patients with liver cirrhosis. Exp Ther Med. 2012;4:972\u20136.","journal-title":"Exp Ther Med"},{"key":"921_CR32","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.25585","volume":"128","author":"CH Hung","year":"2011","unstructured":"Hung CH, Lee CM, Wang JH, et al. Impact of diabetes mellitus on incidence of hepatocellular carcinoma in chronic hepatitis C patients treated with interferon-based antiviral therapy. Int J Cancer. 2011;128:2344\u201352.","journal-title":"Int J Cancer"},{"key":"921_CR33","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1665-2681(19)31462-0","volume":"11","author":"MA Khattab","year":"2012","unstructured":"Khattab MA, Eslam M, Mousa YI, et al. Association between metabolic abnormalities and hepatitis C-related hepatocellular carcinoma. Ann Hepatol. 2012;11:487\u201394.","journal-title":"Ann Hepatol"},{"key":"921_CR34","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/cncr.10662","volume":"95","author":"H Hamada","year":"2002","unstructured":"Hamada H, Yatsuhashi H, Yano K, et al. Impact of aging on the development of hepatocellular carcinoma in patients with posttransfusion chronic hepatitis C. Cancer. 2002;95:331\u20139.","journal-title":"Cancer"},{"key":"921_CR35","first-page":"894","volume":"8","author":"W Ohishi","year":"2003","unstructured":"Ohishi W, Kitamoto M, Aikata H, et al. Impact of aging on the development of hepatocellular carcinoma in patients with hepatitis C virus infection in Japan. Scand J Gastroenterol. 2003;8:894\u2013900.","journal-title":"Scand J Gastroenterol"},{"key":"921_CR36","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.1073\/pnas.242608099","volume":"99","author":"Y Tanaka","year":"2002","unstructured":"Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci U S A. 2002;99:15584\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"921_CR37","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s00535-008-2194-5","volume":"43","author":"D Miki","year":"2008","unstructured":"Miki D, Aikata H, Uka K, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008;43:550\u20137.","journal-title":"J Gastroenterol"},{"key":"921_CR38","first-page":"851","volume":"2","author":"T Honda","year":"2011","unstructured":"Honda T, Miyaaki H, Ichikawa T, et al. Clinical characteristics of hepatocellular carcinoma in elderly patients. Oncol Lett. 2011;2:851\u20134.","journal-title":"Oncol Lett"},{"key":"921_CR39","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1002\/hep.22224","volume":"47","author":"P Singh","year":"2008","unstructured":"Singh P, Coskun ZZ, Goode C, et al. Lymphoid neogenesis and immune infiltration in aged liver. Hepatology. 2008;47:1680\u201390.","journal-title":"Hepatology"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-013-0921-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-013-0921-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-013-0921-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T12:53:10Z","timestamp":1564923190000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-013-0921-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,8]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014,11]]}},"alternative-id":["921"],"URL":"https:\/\/doi.org\/10.1007\/s00535-013-0921-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,8]]}}}